醫療事務聲譽(美國)- 銀屑病關節炎
市場調查報告書
商品編碼
1773145

醫療事務聲譽(美國)- 銀屑病關節炎

Medical Affairs Reputations (US) - Psoriatic Arthritis

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告基於美國風濕病專家的定量回饋,檢視了支持乾癬性關節炎護理的醫療事務團隊的績效和聲譽。報告探討了醫生如何與醫療事務專業人員互動,醫生最重視哪些服務,以及他們對目前產品支援的滿意度。報告還重點介紹了醫生首選的溝通管道和互動頻率、醫生需求未滿足的領域,以及各團隊在關鍵績效領域與競爭對手的比較。

關鍵問題

  • 醫師與醫療事務團隊的互動頻率是增加還是減少?
  • 醫師目前如何使用醫療事務團隊提供的服務?
  • 醫療事務支援的哪些方面對醫師最重要,他們對所提供的支持滿意度如何?
  • 醫師與醫療事務團隊之間喜歡哪種類型的互動,互動頻率如何?
  • 醫療事務團隊在多大程度上滿足了醫師的需求?
  • 醫療事務團隊在特定品牌的表現是低於還是高於預期?
  • 未來如何改善醫療事務服務以滿足醫師的需求?
  • 競爭對手的醫療事務團隊在哪些方面最薄弱,哪些方面最強?

主要品牌

  • Bimzelx (bimekizumab)
  • Cimzia (certolizumab pegol)
  • Enbrel (etanercept)
  • Cosentyx (secukinumab)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Rinvoq (upadacitinib)
  • Simponi (golimumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Stelara (ustekinumab)
  • Taltz (ixekizumab)
  • Xeljanz (tofacitinib)

方法論:

FirstView 報告是基於對通過 LiMATM 遴選的醫生進行的定量調查得出。 LiMATM 是全球最大的醫生名錄,擁有超過 300萬名經過驗證的醫生。每位醫生均根據嚴格的篩選標準精心挑選,以確保收集到的見解具有相關性、可靠性,並反映頂尖醫療專業人士的真實感受和經驗。調查結果以易於理解的圖表形式呈現,方便快速理解和分析資料。 FirstView Reports 憑藉 LiMATM 的廣泛覆蓋面和精準度,提供無與倫比的資料驅動洞察,指導策略規劃,幫助在快速發展的醫療保健領域保持領先地位。

報告有何特別之處?

FirstWord Reports 是值得信賴的行業領導者,致力於製藥業,為生物製藥專業人士和決策者提供詳細且可操作的洞察。深厚的行業知識使能夠提供相關且有價值的洞察,幫助掌握新興趨勢,有效應對複雜挑戰。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解,報告可提供所需的精確度和可靠性。獨家獲取其他地方無法獲得的採訪和資料,以及持續的市場監測,確保全面了解市場動態。報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法,使能夠做出更明智的、資料驅動的決策,在快速變化的行業中保持競爭力。

簡介目錄

This report examines the performance and reputation of Medical Affairs teams supporting psoriatic arthritis therapies, based on quantitative feedback from US rheumatologists. It explores how physicians interact with Medical Affairs professionals, the services they find most valuable, and how satisfied they are with current support by product. The report also highlights preferred channels and frequency of engagement, areas where physician needs are unmet, and how individual teams compare to competitors in key performance areas.

Key Questions Answered:

  • How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • In what ways do physicians currently use the services provided by Medical Affairs teams?
  • What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • How successful are Medical Affairs teams at meeting physician needs?
  • Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Bimzelx (bimekizumab)
  • Cimzia (certolizumab pegol)
  • Enbrel (etanercept)
  • Cosentyx (secukinumab)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Rinvoq (upadacitinib)
  • Simponi (golimumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Stelara (ustekinumab)
  • Taltz (ixekizumab)
  • Xeljanz (tofacitinib)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.